MOTS-c Levels Track Treatment Response in Multiple Myeloma Patients
Background
Multiple Myeloma is an incurable blood cancer characterized by abnormal plasma cell proliferation, often leading to bone damage and kidney failure. Current biomarkers like M-protein and free light chains are crucial for monitoring, but their sensitivity can vary, and there's a need for complementary markers to improve treatment assessment. MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrial-derived peptide known to influence metabolic homeostasis and cellular stress responses. This study investigates if MOTS-c dynamics can serve as a complementary marker for treatment response in newly diagnosed Multiple Myeloma patients.
Results
The study revealed significant and dynamic changes in MOTS-c levels correlating with treatment response. Patients achieving a complete response (CR) demonstrated a substantial 45% reduction in serum MOTS-c levels from baseline to 6 months (p<0.001), a stark contrast to the 10% reduction observed in those with partial response (PR). >
Why It Matters
This research positions MOTS-c as a highly promising complementary biomarker for assessing treatment response in Multiple Myeloma, offering a novel avenue for patient monitoring. Its dynamic changes could enable earlier and more precise evaluation of therapeutic efficacy, potentially guiding timely treatment adjustments and optimizing patient management. Integrating MOTS-c into routine clinical assessment could lead to more personalized treatment strategies and ultimately improve patient outcomes by identifying non-responders sooner. Future studies should validate these findings in larger, multi-center cohorts and explore its utility in predicting relapse and guiding subsequent therapeutic decisions.